{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:31:35Z","timestamp":1770143495894,"version":"3.49.0"},"reference-count":30,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001009","name":"Bristol Myers Squibb Foundation","doi-asserted-by":"publisher","award":["ISR IM101-786"],"award-info":[{"award-number":["ISR IM101-786"]}],"id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,9,30]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, that has been implicated as a biomarker of cardiovascular risk in patients with rheumatoid arthritis (RA). We aimed to investigate how different biologic therapies affect levels of PON1 and oxylipins.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>1213 adult patients with RA in the Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory CoNditions cohort study with moderate-to-high disease activity (Clinical Disease Activity Index (CDAI) &gt;10) who initiated a new biologic (tocilizumab (TCZ), n=296; abatacept, n=374; tumour necrosis factor inhibitors, n=427; rituximab, n=116) were followed prospectively with serum specimens analysed for PON1 activity by arylesterase (ARYL), lactonase (LAC) and PON assays at baseline and after 6 months of biologic therapy. A targeted panel of oxylipins was evaluated by liquid chromatography-mass spectrometry\/mass spectrometry in a subset of patients with the lowest and highest 6-month Disease Activity Score 28 (DAS28)-C reactive protein (CRP) responses in each treatment group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>PON1 activity generally increased in the entire cohort after 6 months of new biologic therapy, showing the greatest, most consistent increases in the TCZ group. Increases in all three PON1 domains associated with significant decreases in disease activity in DAS28-CRP\/CDAI (p&lt;0.05), and increases in LAC\/ARYL were significantly associated with the American College of Rheumatology 20\/50\/70 responses (OR (95% CI) of 1.12 (1.04, 1.22) and 1.13 (1.04, 1.23), p&lt;0.01, respectively), after controlling for other RA disease characteristics. Some oxylipins, including 12-hydroxyeicosatetraenoic acid correlated with RA disease activity measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Improvement in disease activity across four classes of biologics is associated with enhanced PON1 activity, which has significant implications for cardiovascular safety.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004829","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T08:05:20Z","timestamp":1729929920000},"page":"e004829","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-3998","authenticated-orcid":false,"given":"Amir A","family":"Razmjou","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M","family":"Kremer","sequence":"additional","affiliation":[{"name":"Corrona Research Foundation, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-027X","authenticated-orcid":false,"given":"Dimitrios A","family":"Pappas","sequence":"additional","affiliation":[{"name":"Corrona Research Foundation, Albany, New York, USA"},{"name":"CorEvitas LLC, Waltham, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ani","family":"Shahbazian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Elashoff","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Health Services Research, UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Guo","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Health Services Research, UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Meriwether","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawoud","family":"Sulaiman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasa T","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-7019","authenticated-orcid":false,"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"2025090312061639000_10.4.e004829.1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.ATV.21.4.473","article-title":"Paraoxonase and Atherosclerosis","volume":"21","author":"Durrington","year":"2001","journal-title":"ATVB"},{"key":"2025090312061639000_10.4.e004829.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.11.1265"},{"key":"2025090312061639000_10.4.e004829.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"2025090312061639000_10.4.e004829.4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/acr.20237","article-title":"Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis","volume":"62","author":"Rho","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312061639000_10.4.e004829.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.38118"},{"key":"2025090312061639000_10.4.e004829.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210997"},{"key":"2025090312061639000_10.4.e004829.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206411"},{"key":"2025090312061639000_10.4.e004829.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2015.04.088"},{"key":"2025090312061639000_10.4.e004829.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74016-w","article-title":"Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice","volume":"10","author":"Charles-Schoeman","year":"2020","journal-title":"Sci Rep"},{"key":"2025090312061639000_10.4.e004829.10","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R900004-JLR200"},{"key":"2025090312061639000_10.4.e004829.11","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.24867","article-title":"Obesity and Response to Advanced Therapies in Rheumatoid Arthritis","volume":"74","author":"Baker","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312061639000_10.4.e004829.12","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-15-113","article-title":"Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients","volume":"15","author":"Pappas","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"2025090312061639000_10.4.e004829.13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10067-022-06375-w","article-title":"Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis","volume":"42","author":"Razmjou","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025090312061639000_10.4.e004829.14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/rheumatology\/keaa374","article-title":"Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population","volume":"60","author":"L\u00f8gstrup","year":"2021","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090312061639000_10.4.e004829.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223302"},{"key":"2025090312061639000_10.4.e004829.16","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0271-5"},{"key":"2025090312061639000_10.4.e004829.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121389"},{"key":"2025090312061639000_10.4.e004829.18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbrc.2013.06.034","article-title":"Interleukin-6 upregulates paraoxonase 1 gene expression via an AKT\/NF-\u03baB-dependent pathway","volume":"437","author":"Cheng","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"2025090312061639000_10.4.e004829.19","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1527-x","article-title":"Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner","volume":"20","author":"Bozec","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090312061639000_10.4.e004829.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.03.004"},{"key":"2025090312061639000_10.4.e004829.21","doi-asserted-by":"crossref","unstructured":"Webb NR . High-Density Lipoproteins and Serum Amyloid A (SAA). Curr Atheroscler Rep 2021;23. doi:10.1007\/s11883-020-00901-4","DOI":"10.1007\/s11883-020-00901-4"},{"key":"2025090312061639000_10.4.e004829.22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3945\/an.114.007732","article-title":"Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs","volume":"6","author":"Gabbs","year":"2015","journal-title":"Adv Nutr Sep"},{"key":"2025090312061639000_10.4.e004829.23","doi-asserted-by":"crossref","unstructured":"Caligiuri SPB , Parikh M , Stamenkovic A , et al . n.d. Dietary modulation of oxylipins in cardiovascular disease and aging. Am J Physiol Heart Circ Physiol Nov 313:H903\u201318. doi:10.1152\/ajpheart.00201.2017","DOI":"10.1152\/ajpheart.00201.2017"},{"key":"2025090312061639000_10.4.e004829.24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090312061639000_10.4.e004829.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092171"},{"key":"2025090312061639000_10.4.e004829.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204345"},{"key":"2025090312061639000_10.4.e004829.27","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.1264","article-title":"FRI0137\u2005Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis","volume":"72","author":"McInnes","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025090312061639000_10.4.e004829.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209775"},{"key":"2025090312061639000_10.4.e004829.29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/14656566.2022.2076594","article-title":"The management of cardiovascular disease risk in patients with rheumatoid arthritis","volume":"23","author":"Ahmed","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2025090312061639000_10.4.e004829.30","doi-asserted-by":"crossref","unstructured":"Ferreira HB , Melo T , Paiva A , et al . n.d. Insights in the Role of Lipids, Oxidative Stress and Inflammation in Rheumatoid Arthritis Unveiled by New Trends in Lipidomic Investigations. Antioxidants (Basel) 10:45. doi:10.3390\/antiox10010045","DOI":"10.3390\/antiox10010045"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:06:26Z","timestamp":1756926386000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10,26]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/rmdopen-2024-004829"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004829","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}